A 26 week, double blinded, randomized, placebo controlled phase IIa clinical study to investigate the safety, pharmacokinetics and efficacy of oral administration of two doses of odiparcil in patients 16 years and above with MPS type VI receiving enzyme replacement therapy (ERT).
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Odiparcil (Primary)
- Indications Mucopolysaccharidosis VI
- Focus Adverse reactions
- Acronyms iMProveS trial
- 08 Sep 2017 New trial record
- 29 Aug 2017 According to an Inventiva media release, this trial is expected to begin recruitment by year-end 2017.